We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cabergoline Effect on Blood Sugar in Type 2 Diabetics

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2011 by Haleh Rokni Yazdi, Mashhad University of Medical Sciences.
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01459601
First Posted: October 25, 2011
Last Update Posted: October 25, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Haleh Rokni Yazdi, Mashhad University of Medical Sciences
October 24, 2011
October 25, 2011
October 25, 2011
January 2012
February 2012   (Final data collection date for primary outcome measure)
FBS (fasting blood sugar) [ Time Frame: 30days ]
Same as current
No Changes Posted
HbA1C [ Time Frame: 30days ]
Same as current
Not Provided
Not Provided
 
Cabergoline Effect on Blood Sugar in Type 2 Diabetics
Cabergoline Effects on Blood Sugar Control in Type 2 Diabetics
Diabetic patients with poorly control blood sugar are prescribed cabergoline for 1 months and their blood glucose is evaluated.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Diabetes Type 2
Drug: Cabergoline
0,5mg per week
Other Name: Dastinex
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
10
February 2012
February 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Type 2 diabetes
  • HbA1C>7

Exclusion Criteria:

  • HbA1C>10
  • Psychiatric disorders
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01459601
CabergolinDM
No
Not Provided
Not Provided
Haleh Rokni Yazdi, Mashhad University of Medical Sciences
Mashhad University of Medical Sciences
Not Provided
Not Provided
Mashhad University of Medical Sciences
October 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP